Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Call Transcript

We want to be involved, but the key is to have leverage through the power of the data that we’re generating. And we think with the 101 and hopefully 102 following behind data sets that we’re developing. This basically validates the whole 100 Series. And what we’d like to be in a position of leverage in terms of structuring partnerships that allow us to subsidize some of the costs, i.e., capitalization risk but retain significant upside. We also would benefit from the depth of clinical development capabilities from various partners in the checkpoint space. So we’re not adverse to partnering 101 and 102, but we’re certainly not going to hand over the upside of the asset to somebody and just do preclinical work. So we intend to be involved. So we have retained interest and involvement and commercialization rates hopefully in co-development.

But also what you stated, the 300 series is also a natural point for partnering as well. We have a very attractive data set there.

Stephen Willey: All right. It’s very helpful. Thanks for taking the questions.

Dan Passeri: Yes, thank you.

Operator: Thank you. There are no further questions at this time. I’d like to turn the call back to Dan Passeri for closing remarks.

Dan Passeri: Yes. Thank you. Again, I just want to thank everyone for your time and attention during these trying times in the market and really appreciate your time, and we look forward to providing you with ongoing updates particularly midyear, right. Thank you very much. Bye-bye.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation, and have a great day.